Anacor Pharmaceuticals (ANAC)
Anacor Pharmaceuticals Revenues: 2.417M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ANAC Revenues Range, Past 5 Years
| Minimum | 0.71M | Mar 2010 |
| Maximum | 16.90M | Sep 2010 |
| Average | 5.616M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these ANAC related companies
ANAC News
Listen to $ANAC Q1 2012 earnings call - live at 05:00 PM, ondemand after - http://stks.co/3mFo
about 17 days ago by earningscast
about 17 days ago by earningscast
Trading Radar for 05/10: Kohls (KSS), Dynegy (DYN), Express Scripts (ESRX), Molycorp (MCP) Report
May 09, 5:58PM Street Insider
May 09, 5:58PM Street Insider
Listen to $ANAC Anacor Pharmaceuticals Inc at Deutsche Bank AG Health Care Confe - live at 04:10 PM, ondemand after - http://stks.co/3hrk
about 20 days ago by earningscast
about 20 days ago by earningscast
Anacor Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call and Webcast
May 04, 4:00PM Business Wire
May 04, 4:00PM Business Wire
Anacor Pharmaceuticals to Present Clinical Data on Tavaborole and AN2728 at Upcoming Medical Meetings
May 04, 4:00PM Business Wire
May 04, 4:00PM Business Wire
Anacor Pharmaceuticals to Present at the Deutsche Bank Annual Health Care Conference
May 01, 5:00PM Business Wire
May 01, 5:00PM Business Wire
Listen to $ANAC Q4 2011 earnings call - live at 05:00 PM, ondemand after - http://stks.co/2pVQ
about 75 days ago by earningscast
about 75 days ago by earningscast
Anacor Pharmaceuticals Reports 2011 Fourth Quarter and Year-End Financial Results
Mar 13, 4:00PM Business Wire
Mar 13, 4:00PM Business Wire
$ANAC Announces Commencement of Phase 1 Clinical Trials of Boron-Based Compound for Sleeping Sickness
about 76 days ago by Benzinga
about 76 days ago by Benzinga
Anacor Pharmaceuticals Announces Fourth Quarter and Year End 2011 Financial Results Conference Call and Webcast
Mar 06, 4:00PM Business Wire
Mar 06, 4:00PM Business Wire
Canaccord Genuity Maintains a 'Buy' on Anacor Pharmaceuticals (ANAC); Derm Pipeline Priority Shift
Feb 21, 8:41AM Street Insider
Feb 21, 8:41AM Street Insider
$ANAC 200 Day SMA Cross - Price crossed below 200 day SMA (5.9914). Confirmed by volume.
about 102 days ago by TradeIdeasQuant
about 102 days ago by TradeIdeasQuant
Anacor Pharmaceuticals Announces the Sale of 3.25 Million Shares of Common Stock
Feb 08, 4:20PM Benzinga
Feb 08, 4:20PM Benzinga
Canaccord Genuity maintains a 'Buy' on Anacor Pharmaceuticals (ANAC); Positive on Novel Oxaborole Compounds
Feb 06, 8:50AM Street Insider
Feb 06, 8:50AM Street Insider
$ANAC reports partner GlaxoSmithKline $GSK has voluntarily paused enrollment of ongoing GSK '052 Phase 1, 2 Clinical Trials; ANAC halted
about 111 days ago by Street_Insider
about 111 days ago by Street_Insider
$ANAC Announces That Its Partner GSK Has Voluntarily Paused Enrollment of Ongoing GSK '052 Phase 1 and 2
about 111 days ago by Benzinga
about 111 days ago by Benzinga
RT @Benzinga $ANAC Positive Prelim Phase 2 Trial.. C&H breakout too
about 167 days ago by EXPstocktrader
about 167 days ago by EXPstocktrader
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ANAC | 5.37 | +0.00 | +0.00% | 169.16M |
| AN | 36.27 | +0.39 | +1.09% | 4.519B |
| AMZN | 212.89 | -2.35 | -1.09% | 96.88B |
| ALLT | 23.89 | -0.31 | -1.28% | 714.79M |
| ALL | 33.57 | +0.14 | +0.42% | 16.73B |
| ALKS | 16.14 | +0.19 | +1.19% | 2.092B |
| ALK | 33.96 | +0.12 | +0.35% | 2.422B |
| ALIM | 2.63 | +0.00 | +0.00% | 82.66M |
| ALGT | 64.04 | -0.21 | -0.33% | 1.222B |
| ALG | 30.55 | -0.06 | -0.20% | 362.93M |
